Apixaban for the treatment of acute splanchnic vein thrombosis: A pilot study

•Direct oral anticoagulants lack data for splanchnic vein thrombosis (SVT).•This study explores the role of apixaban in SVT.•This study enrolled 23 patients with acute SVT and assessed their bleeding risk.•Apixaban was effective for SVT, but caution is required in liver cirrhosis.

Saved in:
Bibliographic Details
Published inThrombosis research Vol. 237; pp. 181 - 183
Main Authors Kim, Sang-A, Choi, Gwang Hyeon, Lee, Ji Yun, Jang, Eun Sun, Lee, Jeong-Ok, Kim, Jin-Wook, Jeong, Sook-Hyang, Bang, Soo-Mee
Format Journal Article
LanguageEnglish
Published United States Elsevier Ltd 01.05.2024
Subjects
Acute Disease
Adult
Aged
Anticoagulation
Apixaban
Direct oral anticoagulant
Factor Xa Inhibitors - therapeutic use
Female
Humans
Liver cirrhosis
Male
Middle Aged
Pilot Projects
Pyrazoles - therapeutic use
Pyridones - therapeutic use
Splanchnic Circulation - drug effects
Splanchnic vein thrombosis
Venous Thrombosis - drug therapy
Anticoagulation
Direct oral anticoagulant
Splanchnic vein thrombosis
Liver cirrhosis
Apixaban
Online AccessGet full text

Cover

More Information
Summary:•Direct oral anticoagulants lack data for splanchnic vein thrombosis (SVT).•This study explores the role of apixaban in SVT.•This study enrolled 23 patients with acute SVT and assessed their bleeding risk.•Apixaban was effective for SVT, but caution is required in liver cirrhosis.
Bibliography:SourceType-Other Sources-1
content type line 63
ObjectType-Correspondence-1
ISSN:0049-3848
1879-2472
DOI:10.1016/j.thromres.2024.04.002